Cryoport Raises 2026 Outlook After 16% Q1 Sales Gain

Overview

• Cryoport posted first-quarter revenue of $47.8 million, up 16% year over year, led by 26% growth in commercial cell and gene therapy work.
• The company lifted its full-year sales guidance to a range of $192 million to $196 million after stronger orders across services and products.
• Management targets positive adjusted EBITDA in the second half after Q1 improved to a near-breakeven negative $0.6 million.
• The company now supports 766 clinical trials and 21 approved therapies, and its IntegraCell labs completed first clinical shipments from Belgium and the U.S. to trial sites.
• Cryoport reported $403.6 million in cash and investments, funding new supply chain centers slated to open in Paris in Q3 and Santa Ana in Q4.